EAM Investors LLC acquired a new stake in shares of Kite Pharma Inc (NASDAQ:KITE) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 37,995 shares of the biopharmaceutical company’s stock, valued at approximately $2,982,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in KITE. WFG Advisors LP bought a new position in Kite Pharma during the fourth quarter valued at $328,000. Ameritas Investment Partners Inc. bought a new position in Kite Pharma during the first quarter valued at $287,000. BlackRock Inc. raised its position in Kite Pharma by 2.2% in the third quarter. BlackRock Inc. now owns 4,112 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 90 shares in the last quarter. Seven Eight Capital LP bought a new position in Kite Pharma during the fourth quarter valued at $197,000. Finally, Karp Capital Management Corp bought a new position in Kite Pharma during the first quarter valued at $363,000. Hedge funds and other institutional investors own 80.73% of the company’s stock.
Kite Pharma Inc (NASDAQ:KITE) traded up 0.99% during mid-day trading on Wednesday, hitting $71.66. 763,159 shares of the company traded hands. Kite Pharma Inc has a one year low of $39.82 and a one year high of $88.58. The company’s 50-day moving average is $77.72 and its 200-day moving average is $62.61. The stock’s market capitalization is $4.05 billion.
Kite Pharma (NASDAQ:KITE) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by $0.06. The firm had revenue of $9.80 million for the quarter, compared to analyst estimates of $8.85 million. Kite Pharma had a negative return on equity of 39.26% and a negative net margin of 994.89%. Kite Pharma’s quarterly revenue was up 92.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.60) earnings per share. Analysts predict that Kite Pharma Inc will post ($8.16) EPS for the current year.
Several research firms have weighed in on KITE. Raymond James Financial, Inc. lowered shares of Kite Pharma from an “outperform” rating to a “mkt perform” rating in a research note on Monday, May 15th. BTIG Research reiterated a “neutral” rating on shares of Kite Pharma in a research note on Friday, May 19th. Cowen and Company reiterated a “neutral” rating and issued a $74.00 price objective on shares of Kite Pharma in a research note on Tuesday, May 9th. Jefferies Group LLC set a $101.00 price objective on shares of Kite Pharma and gave the company a “buy” rating in a research note on Friday, May 19th. Finally, Stifel Nicolaus lowered shares of Kite Pharma from a “buy” rating to a “hold” rating and set a $74.00 price objective on the stock. in a research note on Friday, March 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. Kite Pharma currently has a consensus rating of “Hold” and a consensus price target of $80.97.
In other news, SVP Jeffrey Wiezorek sold 18,000 shares of the business’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $75.01, for a total value of $1,350,180.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Farah Champsi sold 46,783 shares of the business’s stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $82.80, for a total transaction of $3,873,632.40. Following the completion of the sale, the director now directly owns 79,152 shares of the company’s stock, valued at approximately $6,553,785.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 70,450 shares of company stock valued at $4,863,126 and have sold 540,558 shares valued at $42,856,932. Insiders own 20.60% of the company’s stock.
Kite Pharma Company Profile
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Want to see what other hedge funds are holding KITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kite Pharma Inc (NASDAQ:KITE).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/37995-shares-in-kite-pharma-inc-kite-acquired-by-eam-investors-llc/1850963.html
Receive News & Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.